Evaluating a New Gonadotoxic Risk Stratification System

Description

The primary objective of this study is to assess if there is an association between a newly described gonadotoxic risk stratification system and post-treatment ovarian reserve as determined by FSH and AMH.

Conditions

Cancer

Talk to us

Study Overview

On this page

Study Details

Study overview

The primary objective of this study is to assess if there is an association between a newly described gonadotoxic risk stratification system and post-treatment ovarian reserve as determined by FSH and AMH.

Evaluating a New Gonadotoxic Risk Stratification System

Evaluating a New Gonadotoxic Risk Stratification System

Condition
Cancer
Intervention / Treatment

-

Contacts and Locations

Denver

University of Colorado, Denver, Colorado, United States, 80045

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Female patients ages 8 - 39 years of age
  • * Seen in CHCO or AMC outpatient clinics for any of the following reasons:
  • * At risk for fertility problems (Z91.89)
  • * Encounter for fertility preservation counseling (Z31.62)
  • * Primary ovarian insufficiency
  • * Premature ovarian failure/premature menopause
  • * Diminished ovarian reserve
  • * At least 12 months post-completion of chemotherapy and/or radiation
  • * History of a fertility-threatening diagnosis receiving chemotherapy; radiation; or surgery to the reproductive organs for malignancy, including but not limited to:
  • * Any type of cancer/malignancy
  • * Rheumatoid arthritis
  • * Systemic lupus erythematosus
  • * Aplastic anemia
  • * Fanconi anemia
  • * Diamond-Blackfan syndrome
  • * Hurler syndrome
  • * Other autoimmune conditions
  • * Disorders of sexual development (i.e., gonadal dysgenesis, Turner syndrome/mosaicism, etc.)
  • * History of bilateral oophorectomy
  • * Transgender patients not receiving chemotherapy; radiation; or surgery to the reproductive organs for malignancy
  • * Inability to consent/assent

Ages Eligible for Study

8 Years to 39 Years

Sexes Eligible for Study

FEMALE

Accepts Healthy Volunteers

No

Collaborators and Investigators

University of Colorado, Denver,

Leslie Appiah, MD, PRINCIPAL_INVESTIGATOR, University of Colorado, Denver

Study Record Dates

2028-05